Phase I study of ABBV|428

A Phase 1 Study of ABBV-011 as a Single-Agent and in ...

This is a multicenter, open-label, Phase 1 study of ABBV-011 given as a single agent and in combination with budigalimab (ABBV-181) in participants with ...

A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ...

Study #2016-0618. A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors.

Genmab and AbbVie Announce Positive Topline Results from ...

Company Announcement. Based on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage with global ...

A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally ...

The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a ...

AbbVie Begins Phase 3 Trial for ABBV-383 in Multiple Myeloma ...

ABBV-383 is being tested in a multicenter, randomized, open-label Phase 3 study, where it is being compared to standard therapies in patients with relapsed or ...

Phase 1 Asian PK Study of ABBV-CLS-7262, an eIF2B Activator ...

Phase 1 Asian PK Study of ABBV-CLS-7262, an eIF2B Activator Being Developed as a Potential Treatment for Amyotrophic Lateral Sclerosis and ...

AbbVie and Bristol-Myers Squibb Announce Clinical Research ...

AbbVie (NYSE: ABBV) and Bristol-Myers Squibb Company (NYSE: BMY) today announced a clinical trial collaboration to evaluate the combination ...

A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor ...

The study will consist of 2 phases: Dose Escalation Phase and Expansion Phase ... Dose Escalation Phase: Recommended Phase 2 dose (RPTD) for ABBV-321. Time ...

MA09.09 First-In-Human Phase 1 Study of ABBV-399, an Antibody ...

ABBV-399 is a first-in-class ADC composed of ABT-700, an anti–c-Met antibody, conjugated to monomethyl auristatin E (a microtubule inhibitor). Preclinical data ...

REGENXBIO Announces Lancet Publication of Phase I/IIa Study ...

A single ABBV-RGX-314 gene therapy treatment has the potential to become a new standard-of-care option among anti-VEGF treatments by ...

First-in-human phase I study of ABBV-085, an antibody–drug ...

ABBV-085 is a monomethyl auristatin-E antibody–drug conjugate that targets LRRC15 and showed antineoplastic efficacy in preclinical experiments.

A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally ...

Part 1, ABBV-CLS-484 will be administered alone in escalating dose levels to eligible subjects who have advanced solid tumors. Part 2, ABBV-CLS-484 will be ...

AbbVie Launches Phase I Clinical Trial for ABBV-1882, Promising ...

The treatment, ABBV-1882, is a result of meticulous research and development efforts aimed at addressing the complexities of HIV infection. It ...

SOLID TUMORS - AbbVie Science

DEVELOPMENT. ABBV-706 is being investigated in a Phase 1 trial for the treatment of advanced solid tumors, including small cell lung cancer (SCLC), central ...

First-in-human study of ABBV-400, a novel c-Met

The study is also evaluating ABBV-400 with bevacizumab in pts with CRC. Clinical trial information: NCT05029882. Preliminary efficacy outcomes. CRC Dosing ...

A Phase 1 First-in-Human Study Evaluating Safety ... - UroToday

Study Type: Interventional. Clinical Trials Identifier NCT 8-digits: NCT06318273. Sponsor: AbbVie. Phase: Phase 1. Eligibility: Age: minimum 18 ...

Paper: A First-in-Human Phase 1 Study of ABBV-525, a ... - Abstract

3101 A First-in-Human Phase 1 Study of ABBV-525, a Small-Molecule MALT1 Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin ...

Abbvie M20-247: A Phase 1b Study of ABBV-744 Alone or in ...

An investigational drug is one that is not approved by the FDA. Ruxolitinib is approved for the treatment of myelofibrosis. Neither ABBV-744 nor navitoclax is ...

A Phase 1, Multi-center, Open Label First-in-Human Study With ...

The purpose of this study is to see how safe and effective ABBV-CLS-579 is when used alone or in combination with programmed cell death ...

Phase 3: Intravenous (IV) ABBV-383 Monotherapy Versus Standard ...

ABBV-383 is an investigational drug being developed for the treatment of R/R MM. This study is broken into 2 Arms; Arm A and Arm B. .